JP2017534571A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534571A5
JP2017534571A5 JP2017511183A JP2017511183A JP2017534571A5 JP 2017534571 A5 JP2017534571 A5 JP 2017534571A5 JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017511183 A JP2017511183 A JP 2017511183A JP 2017534571 A5 JP2017534571 A5 JP 2017534571A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
antigen
binding molecule
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017511183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/047174 external-priority patent/WO2016033321A1/en
Publication of JP2017534571A publication Critical patent/JP2017534571A/ja
Publication of JP2017534571A5 publication Critical patent/JP2017534571A5/ja
Withdrawn legal-status Critical Current

Links

JP2017511183A 2014-08-28 2015-08-27 抗体3e10の多価フラグメントおよびその使用方法 Withdrawn JP2017534571A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043228P 2014-08-28 2014-08-28
US62/043,228 2014-08-28
PCT/US2015/047174 WO2016033321A1 (en) 2014-08-28 2015-08-27 Multivalent fragments of antibody 3e10 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019217791A Division JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2017534571A JP2017534571A (ja) 2017-11-24
JP2017534571A5 true JP2017534571A5 (cg-RX-API-DMAC7.html) 2018-10-04

Family

ID=54064606

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017511183A Withdrawn JP2017534571A (ja) 2014-08-28 2015-08-27 抗体3e10の多価フラグメントおよびその使用方法
JP2019217791A Withdrawn JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法
JP2022001621A Pending JP2022037244A (ja) 2014-08-28 2022-01-07 抗体3e10の多価フラグメントおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019217791A Withdrawn JP2020040987A (ja) 2014-08-28 2019-12-02 抗体3e10の多価フラグメントおよびその使用方法
JP2022001621A Pending JP2022037244A (ja) 2014-08-28 2022-01-07 抗体3e10の多価フラグメントおよびその使用方法

Country Status (4)

Country Link
US (2) US20170291961A1 (cg-RX-API-DMAC7.html)
EP (1) EP3194450A1 (cg-RX-API-DMAC7.html)
JP (3) JP2017534571A (cg-RX-API-DMAC7.html)
WO (1) WO2016033321A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) * 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US11613590B2 (en) * 2017-07-17 2023-03-28 Nucleus Therapeutics Pty. Ltd Binding proteins 1
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
BR112021003823A2 (pt) * 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
WO2021077070A1 (en) 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
EP4584292A1 (en) 2022-09-09 2025-07-16 Yale University Proteolysis targeting antibodies and methods of use thereof
WO2024140936A1 (en) * 2022-12-30 2024-07-04 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Humanized cell-penetrating antibodies
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1997032602A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
WO2012145125A1 (en) * 2011-03-25 2012-10-26 4S3 Bioscience Inc. Targeted radionuclides
JP6178785B2 (ja) * 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies

Similar Documents

Publication Publication Date Title
JP2014513069A5 (cg-RX-API-DMAC7.html)
CN112955471B (zh) Cd3抗体及其药物用途
JP6178785B2 (ja) 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
US10238742B2 (en) Cell penetrating nucleolytic antibody based cancer therapy
JP2022037244A (ja) 抗体3e10の多価フラグメントおよびその使用方法
JP2020522254A5 (cg-RX-API-DMAC7.html)
Zhu et al. Multifunctional receptor-targeting antibodies for cancer therapy
JP2020527355A5 (cg-RX-API-DMAC7.html)
JP2009545325A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
AU2018351417B2 (en) Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
JP2020527332A5 (cg-RX-API-DMAC7.html)
JP2018536632A5 (ja) B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
US11608384B2 (en) Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
JP2021501571A (ja) 抗cd3抗体およびそれを含む癌処置用医薬組成物
JP2022506761A5 (cg-RX-API-DMAC7.html)
JP2023545521A5 (cg-RX-API-DMAC7.html)
JP2024532886A5 (cg-RX-API-DMAC7.html)
KR20140067027A (ko) 자가면역 및 염증성 질환의 치료를 위한 방법 및 조성물
JP2023517754A5 (cg-RX-API-DMAC7.html)
JP6876006B2 (ja) 癌免疫療法に使用するための二重特異性抗体
CN117561276A (zh) 抗cd98抗体及其应用
CN114616246B (zh) 卷曲受体抗体及其用途
CN115698077A (zh) 结合bcma的单可变结构域及抗原结合分子
JP2024515165A5 (cg-RX-API-DMAC7.html)